1. Home
  2. Material Detail: BNT162b2 mRNA COVID-19 Vaccine: First Approval - PubMed

Material Detail

BNT162b2 mRNA COVID-19 Vaccine: First Approval - PubMed

BNT162b2 mRNA COVID-19 Vaccine: First Approval - PubMed

BNT162b2 (Comirnaty<sup>®</sup>; BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Keyword:
COVID-19
Disciplines:
Go to Material 
Bookmark / Add to Course ePortfolio
Create a Learning Exercise
Add Accessibility Information
Rate
Add a Comment

Quality

  • Editor Reviews
  • User Rating
  • Comments
  • Learning Exercises
  • Bookmark Collections
  • Course ePortfolios
  • Accessibility Info

More about this material

Material Type:
Reference Material
Date Added to MERLOT:
August 17, 2021
Date Modified in MERLOT:
August 17, 2021
Author:
Unknown (Know the author?)
Submitter:
Mary Bemker
Primary Audience:
College Upper Division, Graduate School, Professional
Technical Format:
Website
Mobile Compatibility:
Not specified at this time
Technical Requirements:
Accessed via Google Chrrome.
Language:
English
Cost Involved:
No
Source Code Available:
Yes
Accessibility Information Available:
Unknown
Creative Commons:
Unknown

Browse...

Disciplines with similar materials as BNT162b2 mRNA COVID-19 Vaccine: First Approval - PubMed
People who viewed this also viewed
Other materials like BNT162b2 mRNA COVID-19 Vaccine: First Approval - PubMed

Comments

Log in to participate in the discussions or sign up if you are not already a MERLOT member.